This multi-targeted TKI demonstrated efficacy against MET (mesenchymal–epithelial transition, a prototypical receptor tyrosine kinase, whose alterations are drivers of human cancer), ALK, and ROS1 (ROS proto-oncogene 1, a receptor tyrosine kinase, which is involved in genetic rearrangement in a variety of human cancers), ALK, and ROS1, and was proven to improve progression-free survival (PFS) compared with traditional chemotherapy (median 10.9 months vs. 7.0 months; HR 0.45; 95% CI 0.35–0.60; p < 0.001) in patients with ALK-positive lung cancer (Shaw et al., 2103). Here, ROS1 is linked to lung carcinoma.